Editas Medicine, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026.

Key Highlights

  • Net loss: The company reported a net loss of $23,393 thousand for the three months ended September 30, 2026, compared to a net loss of $25,117 thousand in the same period of 2025.
  • Nine-month net loss: For the nine months ended September 30, 2026, the net loss totaled $66,605 thousand, versus $154,440 thousand in the prior-year period.
  • Collaboration revenues: Collaboration and other research and development revenues were $10,365 thousand for Q3 2026, up from $7,543 thousand in Q3 2025.
  • Share count increase: Common shares outstanding rose from 97,866,996 at December 31, 2025 to 153,657,962 at September 30, 2026, following an issuance of 55,555,556 shares and warrants from a financing transaction in Q2 2026.
  • Cash and investments: Cash and cash equivalents stood at $93,169 thousand and marketable securities at $97,029 thousand as of September 30, 2026, compared to $146,645 thousand in cash and no marketable securities at December 31, 2025.
  • Total stockholders' equity: Total stockholders' equity was $84,520 thousand at September 30, 2026, up from $27,288 thousand at December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $1,695,108 thousand as of September 30, 2026.

Editas Medicine Financial Results for the Quarter Ended September 30, 2026

According to the filing, Editas Medicine (NASDAQ:EDIT) reported a net loss of $23,393 thousand, or $0.15 per share basic and diluted, for the three months ended September 30, 2026, based on weighted-average common shares outstanding of 153,604,267. This compares to a net loss of $25,117 thousand, or $0.28 per share, for the same quarter in 2025, when weighted-average shares outstanding were 90,090,397. The company disclosed that collaboration and other research and development revenues increased to $10,365 thousand in Q3 2026 from $7,543 thousand in Q3 2025.

Total operating expenses for the three months ended September 30, 2026 were $34,647 thousand, the filing stated, comprising research and development expenses of $21,170 thousand and general and administrative expenses of $13,477 thousand. For the nine months ended September 30, 2026, the company disclosed a significant reduction in restructuring and impairment charges, reporting a credit of $1,339 thousand compared to $66,935 thousand in the nine months ended September 30, 2025, contributing to a narrower year-to-date operating loss of $67,839 thousand versus $152,255 thousand in the prior-year period.

On the balance sheet, total assets were $219,412 thousand at September 30, 2026, up from $186,534 thousand at December 31, 2025. The company disclosed that it completed a financing in Q2 2026 that resulted in the issuance of 55,555,556 shares of common stock and warrants to purchase future common stock, generating proceeds of $116,880 thousand. Deferred revenue, current, was $32,315 thousand at September 30, 2026, compared to zero at year-end 2025, while deferred revenue, net of current portion, decreased from $44,509 thousand to $4,000 thousand over the same period. As of November 6, 2026, the company reported 154,339,748 shares of common stock outstanding.

What Was Disclosed

Editas Medicine filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $23,393 thousand, increased collaboration revenues, a significant share issuance completed during Q2 2026, and total assets of $219,412 thousand.